Advancements and limitations in traditional anti-cancer therapies: a comprehensive review of surgery, chemotherapy, radiation therapy, and hormonal therapy.
Zafar A, Khatoon S, Khan MJ, Abu J, Naeem A. · 2025
Read Advancements and limitations in traditional anti-cancer therapies: a comprehensive review of surgery, chemotherapy, radiation therapy, and hormonal therapy. by Zafar A, Khatoon S, Khan MJ, Abu J, Naeem A. (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc12021777.txt.
Introduction
Zafar and co-authors reviewed classic cancer treatments in 2025. Cancer is the second leading cause of death worldwide. Four long-used treatments anchor much of care. They are surgery, chemotherapy, radiation, and hormonal therapy.
Surgery now gains from glowing dyes and robotic arms. Radiation has sharper focus and three-dimensional planning. Chemotherapy drugs have grown stronger and more targeted over time. Hormonal therapy curbs cancers that feed on hormones. Zafar also stresses the limits each method still faces. The review helps readers weigh gains against harms. It appeared in Discover Oncology in 2025.
Catalog record
| CREATOR | Zafar A, Khatoon S, Khan MJ, Abu J, Naeem A. |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 87 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Advancements and limitations in traditional anti-cancer therapies: a comprehensive review of surgery, chemotherapy, radiation therapy, and hormonal therapy By Aasma Zafar, Summaiya Khatoon, Muhammad Jawad Khan, Junaid Abu, Aisha Naeem Published in: Discover Oncology DOI: 10.1007/s12672-025-02198-8 ABSTRACT Abstract Cancer remains a major global health challenge, consistently ranking as the second leading cause of mortality worldwide. Despite significant advancements in research and technology, the need to deepen our understanding of tumor biology and improve therapeutic strategies persists. This review focuses on the progress and challenges of four traditional cancer treatment modalities: surgery, chemotherapy, radiation therapy, and hormonal therapy. Surgery, the primary method for tumor removal, has evolved with the integration of fluorescence-based technology and robotic systems, enhancing precision and minimizing collateral damage. Radiation therapy has progressed with improved focus, intensity control, and 3D technology, refining both diagnosis and treatment. Chemotherapy has advanced from natural extracts to synthesized derivatives with amplified cytotoxicity against cancer cells. Hormonal therapy has emerged as a crucial strategy for hormone-dependent cancers, restraining growth or inducing regression. Despite these advancements, each approach faces ongoing challenges. Surgery struggles with complete tumor removal due to heterogeneity. Chemotherapy contends with drug resistance and side effects. Radiation therapy grapples with precision issues and limited access in some regions. Hormonal therapy faces resistance development and quality of life impacts. This study provides a comprehensive analysis of the evolution of these traditional anti-cancer therapies, offering insights into their progress and highlighting areas for future research. By examining these modalities, we aim to underscore their relevance in the current oncology landscape and identify opportunities for improvement in cancer treatment strategies. Keywords: Cancer, Anticancer therapies, Surgery, Hormonal therapy, Antimetabolites INTRODUCTION Cancer, characterized by the unwanted proliferation of cells arising from an aggregation of various genetic anomalies, including dysregulation of genes and their regulators, has a deep-rooted history dating back approximately 1.98 million years. Evidence of tumors, specifically osteosarcoma, has been discovered in human fossils from South Africa, showcasing the ancient existence of this disease [1]. Historical records indicate cancer as the reported cause of death in Egyptian mummies dating back to around 1500 BC [1]. The term “cancer,” coined by the Greek physician Hippocrates, derives from the disease’s crab-like projections as it spreads into adjacent tissues [2]. In the fifteenth century, a Roman physician introduced the term “oncos” to describe swelling, highlighting early attempts to understand and categorize tumors. During that period, the only available treatment option involved herbal medication or the application of a poultice near the cancer following a restricted incision [3]. In the fifteenth century, a greater understanding of the structure and functioning of the human body, tumor biology, and the discovery of anesthesia prompted physicians to consider surgery as the most viable option for cancer treatment. The persistent rise in cancer-related deaths, coupled with the inherent risks and severe side effects of existing treatments, highlights the urgent need for more effective and personalized options. Despite the emergence of advanced therapies such as immunotherapy and gene therapy, traditional treatments remain the most commonly adopted due to their cost-effectiveness and widespread use. Therefore, ongoing efforts to improve and refine conventional cancer treatments—such as surgery, radiotherapy, chemotherapy, and hormonal therapy—remain essential, as illustrated in Fig. 1. This review aims to provide a comprehensive overview of the advancements and limitations of these traditional therapies. By exploring their current state, evolutionary progress, and enduring challenges, we seek to identify areas of unmet need and highlight potential avenues for future research and innovation. [Figure: Evolution and milestones of traditional anticancer therapies across centuries: A comprehensive overview of development and progress] SURGERY Surgery is a time-honored and fundamental practice for treating and diagnosing solid malignancies. In diagnostics, cancerous tissue biopsy is the optimal choice for subtyping and grading cancers; however, insufficient sample size and routine painful monitoring limit its effectiveness. Recently developed liquid biopsy offers non-invasive monitoring of cancer-specific biomarkers such as circulating tumor DNA (ctDNA), circulating tumor cells (CTC), and Extracellular vesicles (EV), which are released by primary tumors for metastasis [4]. However, identifying novel cancer-specific biomarkers and highly sensitive technology to detect the minor quantity of biomarkers is indispensable for effective diagnosis at early stages of disease. Excision surgery is performed to achieve complete clearance of tumor cells. However, despite apparently successful resection, residual disease often remains in the clearance margins, microscopic deposits, and micro-metastases (stromal or hematogenous), indicating the presence of minimal residual disease (MRD) [5]. Studies have shown that MRD can progress rapidly, and the surgical removal of the tumor mass often correlates with this progression [6]. The aggressive nature of MRD can be attributed to various factors, including the surgical technique itself and the trauma-induced environment, which may foster conditions that promote cancer cell proliferation. Perioperative factors, such as the use of opioids for pain management and blood transfusions, may further contribute to this phenomenon [7]. The post-surgical introduction of immunosuppressors to aid wound healing facilitates the evasion of tumor cells from the immune system. This results in decreased natural killer (NK) cytotoxicity and compromised macrophage function linked to increased tumor growth post-surgery [7]. Surgical intervention may also reduce circulating dendritic cells (DC), which are crucial for immune surveillance following tumor removal [7]. Additionally, removing antiangiogenic factors released by the primary tumor facilitates neovascularization potential in micro-metastases at other sites, exacerbating disease progression. The surgical removal of the primary tumor frees MRD from inhibitory control, known as concomitant tumor resistance, leading to the unhindered growth of metastatic foci [7]. Proangiogenic factors secreted by primary tumor cells promote the establishment of new vessels at the primary site, fostering cancer progression [7]. Additionally, removing antiangiogenic factors released by the primary tumor facilitates neovascularization potential in micro-metastases at other sites, sparking disease progression. The surgical removal of the tumor reduces levels of antiangiogenic factors and increases the presence of angiogenic factors. This shift empowers previously inactive micro-metastases to undergo angiogenesis, ultimately exacerbating the progression of the disease [7]. To address the complications associated with traditional surgery, numerous technological advancements have been introduced over the years, shifting from open surgery to minimally invasive techniques, such as laparoscopic surgery, which reduces blood loss and lowers morbidity (Fig. 1). Cryo-technology and laser techniques have improved surgical precision, while fluorescence-guided surgery (FGS) allows surgeons to distinguish between tumor and normal cells, helping to delineate tumors and avoids leaving behind cancerous tissue or damaging surrounding healthy cells [8]. Video-assisted laparoscopic surgery (VALS) enhances precision by offering real-time visualization, though its two-dimensional view and limited maneuverability in tight spaces present challenges [9]. The advent of robotic surgery has provided surgeons with greater control, precision, and flexibility, while allowing them to view the surgical area in magnified three-dimensional images [10]. Over time, the autonomy of surgical robots has increased, evolving from mere assistants to systems capable of developing personalized surgical strategies [11]. This increased autonomy enables surgeons to plan and execute complex surgeries with enhanced precision and tailored approaches. Although these technological advancements have allowed surgeons to reduce the chances of minimal residual disease (MRD) and surgical stress, advancements like robotic surgery have minimized errors in the removal of tumor tissue, which can sometimes trigger the emergence of metastatic loci. Surgical intervention also carries potential complications, including infections, impaired quality of life, and challenges